Agree Realty (ADC 1.05%) has been a popular stock in 2024, with a share price gain of more than 15%. That's roughly three times the return of the average real estate investment trust (REIT). Although Agree's dividend yield is above the REIT average at around 4% (versus the 3.7% average), it might be time to consider a value-conscious alternative. Here's the biggest option that you should be looking at today. There are a lot of reasons to like Agree RealtyAgree Realty is a very well-run net lease REIT (a net ...

Core Insights - Aadi Bioscience has entered into an exclusive license agreement for a three-asset antibody-drug conjugate (ADC) portfolio developed in collaboration with WuXi Biologics and HANGZHOU DAC, focusing on preclinical ADC programs targeting PTK7, MUC16, and SEZ6 [1][2] - The company is selling its FYARRO product and associated infrastructure to KAKEN Pharmaceutical for $100 million, with the transaction expected to close in the first half of 2025 [11][12] - Aadi has announced a PIPE financing of $100 million to support its operations and fund the ADC portfolio development into late 2028 [3][14] License Agreement Details - Aadi will pay $44 million in upfront payments for the ADC programs and is obligated to pay up to $265 million in development milestone payments and up to $540 million in commercial milestone payments, along with single-digit royalties on sales [2] - The ADC assets utilize HANGZHOU DAC's CPT113 platform, which features a stable yet cleavable linker delivering a Topoisomerase I inhibitor payload, positioning them competitively among next-generation ADC platforms [6][7] Financial Transactions - The PIPE financing involves the sale of 21,592,000 shares at $2.40 per share, representing a 3.4% premium to the closing price on December 19, 2024 [3][4] - The net proceeds from the PIPE financing and the sale of FYARRO are expected to fund operations into late 2028, including anticipated clinical data readouts for the ADC portfolio [14] Management and Board Changes - Baiteng Zhao, co-founder and former CEO of ProfoundBio, has been appointed to Aadi's Board of Directors, bringing significant expertise in ADC development [15][16] - Zhao expressed optimism about the potential of the ADC targets and the advanced linker-payload platform, indicating Aadi's strong position to impact patient outcomes [17] Product and Market Focus - The ADC portfolio targets tumor markers that are overexpressed in various cancers, including non-small cell lung cancer and cancers of female origin, aiming to improve treatment outcomes [7][8] - The collaboration with WuXi Biologics and HANGZHOU DAC emphasizes the innovative approaches in ADC development, leveraging advanced discovery technologies [10]

Core Insights - Mersana Therapeutics is an early phase biotech company that has encountered difficulties in recent years, leading to the shelving of several clinical candidates that were once considered promising [1] Company Overview - Mersana Therapeutics operates in the biotechnology sector and has faced significant challenges, particularly in the development of its clinical candidates [1] Industry Context - The biotech industry is characterized by high risks and potential pitfalls, necessitating thorough due diligence by investors to avoid losses [1]

Dividend growth stocks aren't always the most exciting investments out there. They often aren't grabbing the headlines, and they aren't theFor some background on this monthly publication, here is my view on dividend growth stocks :Interested in more income ideas? Check out Cash Builder Opportunities, where we provide ideas about high-quality and reliable dividend growth ideas. These investments are designed to build growing income for investors. A special focus on investments that are leaders within their i ...

Contributing analyst to the iREIT+Hoya Capital investment group. The Dividend Collectuh is not a registered investment professional nor financial advisor and these articles should not be taken as financial advice. This is for educational purposes only and I encourage everyone to do their own due diligence. I'm a Navy veteran who enjoys dividend investing in quality blue-chip stocks, BDC's, and REITs. I am a buy-and-hold investor who prefers quality over quantity and plans to supplement his retirement income ...

Core Viewpoint - Agree Realty (ADC) offers a 4.1% dividend yield, slightly above the REIT sector average of 3.7%, but below the 5.6% yield from Realty Income, raising questions about its premium price for investors aiming for substantial portfolios [1] Group 1: Company Overview - Agree Realty is a net lease REIT with over 2,200 properties, providing significant diversification and reducing risk associated with single-tenant leases [2] - The company focuses on retail assets, which are easier to manage and trade, operating in a U.S. retail net lease market valued at approximately $1.5 trillion [3] - Agree Realty actively manages its portfolio by selling properties from weaker tenants like Walgreens and acquiring from stronger retailers such as Tractor Supply and TJX Companies [4] Group 2: Financial Strength - The company maintains a strong balance sheet with an investment-grade credit rating, allowing it to issue debt at favorable rates and withstand financial challenges without jeopardizing its dividend [5] - Over the past decade, Agree's dividend has grown at a compound annual rate of roughly 6%, significantly outpacing Realty Income's growth rate [7] Group 3: Investment Potential - Agree Realty's smaller size compared to Realty Income allows for easier business growth with less investment volume needed to impact financial results [6] - The company's share price has nearly returned to pre-pandemic levels, indicating strong growth potential, while Realty Income's stock remains below early 2020 levels [8] - Agree Realty is positioned as a growth and income stock, appealing to investors looking for long-term wealth accumulation rather than immediate income [9]

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Licensing agreement gives Elevation Oncology access to Synaffix's ADC technology for one program in combination with SYNstatin E™ Elevation Oncology nominates a novel HER3 ADC candidate EO-1022 leveraging its antibody as well as Synaffix's proprietary ADC development technologiesAMSTERDAM, Dec. 12, 2024 /PRNewswire/ -- Synaffix B.V., a Lonza company (SIX: LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therape ...

-- EO-1022 is comprised of seribantumab, an anti-HER3 monoclonal antibody, and an MMAE payload –-- Following recently signed global license agreement with Synaffix, EO-1022 leverages the company's GlycoConnect® and HydraSpace® ADC technologies for glycan site-specific conjugation and SYNstatin E™ linker-payload --– Elevation Oncology expects to present EO-1022 preclinical data in 1H 2025 and to file an IND application in 2026 –BOSTON, Dec. 12, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an ...

You won't be charged a penny during the free trial, so you have nothing to lose and everything to gain.If you want full access to our Portfolio and all our current Top Picks, feel free to join us at High Yield Landlord for a 2-week free trial.The Fed has already cut interest rates two times, and it is expected to cut rates again at the next meeting on December 18th.He is the leader of the investing group High Yield Landlord , where he shares his real-money REIT portfolio and transactions in real-time. Featu ...